Business

Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock

NEWTOWN, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on

articleSolana CompanyNovember 9, 20215/company/helius-medical-technologies-inc-class-a/news/helius-medical-technologies-inc-announces-proposed-underwritten-public-offering-of
Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock

About this update from Solana Company

[{"type":"text","content":"NEWTOWN, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has commenced a proposed underwritten registered public offering of shares of its common stock. All of the shares of common stock to be sold in the proposed offering will be sold by the Company. In addition, the Company intends to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this proposed offering for funding operations, working capital and other general corporate purposes. Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the offering. The proposed offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-236101) that was declared effective by the U.S. Securities and Exchange Commission (“SEC”), on February 6, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th floor, New York, NY 10019 by email at [email protected]. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. About Helius Medical Technologies, Inc. Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself....

More updates from Solana Company